Rituximab Biosimilar – Research Grade: LALAPG [ICH4011LALAPG]

ichorbio’s Rituximab Biosimilar – Research Grade is manufactured in a cGMP compliant facility. This version of rituximab is Fc Silenced using the LALAPG mutation

ichorbio’s research grade rituximab biosimilar is available in the following sizes:
0.5mg, 1mg, 5mg, 10mg, 20mg
ichorbio regularly manufactures bulk multi-gram amounts of our Fc silenced rituximab biosimilar – please contact us for pricing.

CD20

n/a

Human IgG1-Kappa

B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, MS4A1

Humanized

Human

Detects human CD20. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Rituximab with a LALAPG mutation in the Fc region. ichorbio’s rituxumab biosimilar is for research use only (RUO).

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD. ichorbio’s Rituximab is produced in mammalian cells -Chinese Hamster Ovary.

1.0 – 5.0 mg/ml

Sterile, clear, colorless, preservative-free solution containing polysorbate 80, sodium chloride, sodium citrate. The pH is 6.5. BSA and Azide free.

>95% by SDS-PAGE and HPLC

≤ 0.75 EU/mg as determined by the LAL method

Rituximab Biosimilar – Research Grade: LALAPG is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Functional Assays

Each investigator should determine their own optimal working dilution for specific applications.